Breast cancer has become the most frequently diagnosed cancer in women, and is the second leading cause of death in women. Although relatively ineffective, Mouse Double Mouse Minute 2 (MDM2) inhibitors blocking the MDM2-p53-binding interphase are currently used for the treatment of advanced breast cancer. This new technology targets a novel direct inhibitor of the MdM2 gene --SP141-- that has shown to possess in vitro and in vivo anti-breast cancer activity, with no seen toxicity.
- Cancer Diagnostics
- In Vitro Diagnostics
Features, Benefits & Advantages:
High throughout screening, and computer aided structure-based rational drug design have shown that SP-141 is a novel therapeutic target for the inhibition of the advancement of breast cancer. SP-141 has shown to inhibit tumor growth in vivo, induce MDM2 protein degradation, and inhibit cell migration in vitro and in vivo.
- Novel, less invasive treatment.
- Less side effects than other drugs currently on the market
Initial clinical tests have been completed and analyzed to obtain information regarding the efficacy and safety of the compound, as well as its therapeutic value.
The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Wang et al., Nat Commun. 2014 Oct 1;5:5086